Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Free Cash Flow for 10 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 795.14% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.7 million through Dec 2025, up 266.37% year-over-year, with the annual reading at $67.7 million for FY2025, 266.37% up from the prior year.
  • Free Cash Flow for Q4 2025 was $31.1 million at Akebia Therapeutics, up from $28.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $33.8 million in Q3 2022, with the low at -$70.8 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$16.1 million, with a median of -$11.8 million recorded in 2024.
  • The sharpest move saw Free Cash Flow crashed 378.18% in 2024, then soared 795.14% in 2025.
  • Over 5 years, Free Cash Flow stood at -$62.8 million in 2021, then increased by 12.94% to -$54.7 million in 2022, then skyrocketed by 95.78% to -$2.3 million in 2023, then plummeted by 93.59% to -$4.5 million in 2024, then skyrocketed by 795.14% to $31.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $31.1 million, $28.0 million, and $22.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.